Clinical trials: Osteoporosis
Postmenopausal Osteoporosis
A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis
The purpose of this trial is to study the efficacy of a 35 mg delayed release weekly dosing regimen as compared to the standard daily dosing regimen of risedronate 5 mg daily.
- Trial name
- NCT00541658
- Testing
- risedronate
- Where
- 45 sites in United States, Argentina and 6 more
- Volunteers
- 923 people
- Sponsor
- Warner Chilcott
Postmenopausal Osteoporosis
Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women
To evaluate the effect of 1 year of risedronate treatment on the prevention of bone loss after denosumab discontinuation in denosumab-treated post-menopausal osteoporosis for a year
- Trial name
- NCT05630768
- Testing
- Risedronate Sodium 35 MG [Actonel], Calcium Vitamin D combination
- Where
- South Korea
- Volunteers
- 149 people
- Sponsor
- Dong-A ST Co., Ltd.
Postmenopausal Osteoporosis
A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)
This study is to evaluate and compare the effects of Alendronate and Risedronate to treat women with postmenopausal osteoporosis.
- Trial name
- FACT (NCT00092014)
- Testing
- Alendronate, Risedronate 35 mg, Elemental Calcium
- Volunteers
- 1,053 people
- Sponsor
- Organon and Co
Osteoporosis, Postmenopausal
A Study to Determine the Satisfaction With Actonel in Postmenopausal Women With Osteoporosis
The study in the labeled and real conditions of prescription of Actonel will investigate the satisfaction of patients with its new formulation: 35 mg Once A Week.
- Trial name
- ROSPA-CTx (NCT00632216)
- Testing
- Risedronate Sodium
- Volunteers
- 464 people
- Sponsor
- Sanofi
Osteoporosis
Feasibility of Doctors' Rooms-based Infusion of Zoledronic Acid
1. The study will assess the safety and tolerability of a single-infusion of zoledronic acid 5 mg administered in a private medical practice setting by a nurse provided by a nationwide infusion service.
- Trial name
- LISA (NCT00745485)
- Testing
- zoledronic acid
- Where
- 14 sites in Australia
- Volunteers
- 186 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis
Analysis of Iliac Crest Biopsies From Patients Receiving Risedronate
This study analysed and reported on the study data from three similar, risedronate studies, 1996052, 2003073, and 2003096. The objective of the study was to determine the differences in the iliac crest bone histomorphometry and…
- Trial name
- NCT00837746
- Testing
- risedronate
- Where
- 8 sites in United States, Canada
- Volunteers
- 29 people
- Sponsor
- Warner Chilcott
Osteoporosis
Efficacy and Safety of Zoledronic Acid for the Treatment of Osteoporosis in Men
The goal of this study is to determine the effectiveness and safety of an annual intravenous treatment of zoledronic acid for the treatment of osteoporosis in men. All patients will receive calcium and vitamin D supplements.
- Trial name
- NCT00097825
- Testing
- Zoledronic Acid
- Where
- 26 sites in United States, Australia and 1 more
- Volunteers
- 288 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis, Postmenopausal
Julina Post-marketing Surveillance for Climacteric Symptoms in Japan
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Julina for postmenopausal osteoporosis.
- Trial name
- JULINA-CLIMA (NCT01386281)
- Testing
- E2 transdermal (Julina, BAY86-5435)
- Where
- Japan
- Volunteers
- 506 people
- Sponsor
- Bayer
Low Bone Mass, Low Bone Mineral Density
Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis
The purpose of this study is to assess how effective and safe denosumab is in a population of males with low bone mass at risk of fracture.
- Conditions
- Low Bone Mass, Low Bone Mineral Density, Males With Osteoporosis, Osteopenia
- Trial name
- NCT00980174
- Testing
- 60 mg denosumab
- Volunteers
- 242 people
- Sponsor
- Amgen
Low Bone Density, Osteopenia
Safety and Pharmacokinetics of Orally Administered Strontium L-Lactate in Healthy Adults
No clinical trials have evaluated strontium L-lactate (SrLac), the strontium salt of the L-enantiomer of lactic acid. Therefore, this clinical study was conducted to obtain general safety and pharmacokinetic (PK) information…
- Conditions
- Low Bone Density, Osteopenia, Osteoporosis, Postmenopausal
- Trial name
- NCT03761979
- Testing
- Strontium L-lactate
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- BioLink Life Sciences, Inc.
Osteoporosis, Postmenopausal, Bone Density, Low
The Effect of the Probiotic Strains on Bone Mineral Density in Postmenopausal Women
Osteoporosis is a systemic condition characterized by low bone mass and altered bone tissue microarchitecture, with the resulting greater bone fragility leading to fractures.
- Trial name
- NCT06375668
- Testing
- Probiotic
- Where
- 3 sites in Poland
- Volunteers
- 170 people
- Sponsor
- Nordic Biotic Sp. z o.o.
Osteoporosis Diagnosis
Bone Evaluation by Ultrasound Radiofrequency Echographic Multi Spectrometry (REMS) vs Dual X-ray Absorptiometry (DXA)
Bone Density Evaluation by means of the Ultrasound Technology Named Radiofrequency Echographic Multi Spectrometry (REMS) in Comparison With DXA Technique.
- Trial name
- NCT06371755
- Testing
- Ultrasound examination with REMS technology
- Where
- Italy
- Volunteers
- 296 people, healthy volunteers welcome
- Sponsor
- Paola Pisani
Glucocorticoid Induced Osteoporosis
Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis
This is a randomized, double-blind, double-dummy, positive-controlled phase II interventional study designed to evaluate the efficacy and safety of JMT103 in the treatment of glucocorticoid induced osteoporosis patients.
- Trial name
- NCT05397938
- Testing
- JMT103, Alendronate sodium
- Where
- China
- Volunteers
- 231 people
- Sponsor
- Shanghai JMT-Bio Inc.
Healthy
Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of Single and Multiple-Doses of ATF936 and AXT914 Administered Orally in Healthy Subjects.
This is a first-in-human study and is designed to evaluate the safety, tolerability, pharmacodynamic and pharmacokinetic effects of a single and multiple-doses of ATF936 and AXT914 administered orally in healthy subjects.
- Trial name
- NCT00417261
- Testing
- ATF936, AXT914
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Novartis
Postmenopausal Osteoporosis
Study of Transitioning From Alendronate to Denosumab
The study will evaluate the efficacy and safety of transitioning postmenopausal women on current alendronate therapy to denosumab.
- Trial name
- NCT00377819
- Testing
- alendronate, Denosumab (AMG 162)
- Volunteers
- 504 people
- Sponsor
- Amgen
Risk Factors for or a Diagnosis of Osteoporosis
Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone
The purpose of this study is to determine the maximum tolerated concentration (MTC) of bisphosphonate with a fixed dose of rHuPH20 administered SC, the MTC of bisphosphonate without rHuPH20 administered SC, the optimal dose of…
- Trial name
- NCT00807963
- Testing
- rHuPH20, zoledronic acid
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Halozyme Therapeutics
Osteoporosis, Osteoarthritis
OSTEOMICS: Identifying Regulators of Bone Homeostasis
Diseases of bone associated with ageing, including osteoporosis (OP) and osteoarthritis (OA), reduce bone mass, bone strength and joint integrity.
- Conditions
- Osteoporosis, Osteoarthritis, Bone Diseases, Bone Fracture
- Trial name
- OSTEOMICS (NCT05732870)
- Testing
- Relevant orthopaedic surgery
- Where
- 8 sites in United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Relation Therapeutics
Osteoporosis
A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women
This study compares the performance of different doses of oral recombinant salmon calcitonin (rsCT).
- Trial name
- NCT00620854
- Testing
- Recombinant Salmon Calcitonin (rsCT), Oral Tablet, Nasal Spray
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Tarsa Therapeutics, Inc.
Osteoporosis
Teriparatide Use in Hip Replaced Subjects
A pilot study on the use of Teriparatide in severe osteoporotic women with hip fracture and submitted to hip replacement The primary objective of this study is to obtain preliminary data, in a pilot group of postmenopausal women…
- Trial name
- NCT00191321
- Testing
- Teriparatide
- Where
- 11 sites in Italy
- Volunteers
- 60 people
- Sponsor
- Eli Lilly and Company
Osteoporosis
Clinical Trial of Teriparatide in Japan
The purpose of this study is to assess the Efficacy and Safety of Teriparatide in Japanese Postmenopausal Women with Osteoporosis.
- Trial name
- NCT00191867
- Testing
- Teriparatide
- Where
- 6 sites in Japan
- Volunteers
- 160 people
- Sponsor
- Eli Lilly and Company